PTC596 is primarily explored for its potential in cancer therapy, particularly in targeting and inhibiting the growth of cancer cells. It functions by disrupting the activity of BMI-1, a protein that plays a key role in the survival and proliferation of cancer stem cells. This makes PTC596 a promising candidate for treating various cancers, including those that are resistant to conventional therapies. Research has shown its efficacy in preclinical models of leukemia, ovarian cancer, and other malignancies, where it reduces tumor growth and enhances the effectiveness of other anticancer treatments. Its ability to target cancer stem cells, which are often responsible for relapse and metastasis, positions it as a valuable tool in developing advanced cancer therapies.